

Response to paper by Binkowska *et al.* Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy

Jonathan Douxfils¹, Jean-Michel Foidart², Ulysse Gaspard², Guillaume Chatel³, Mélanie Taziaux³, Maud Jost³, Céline Gérard³, Laure Morimont¹

¹Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium

²Department of Gynecology, University of Liège, Liège, Belgium

³Mithra Pharmaceuticals, Liège, Belgium

To the Editors,

We read with great interest the manuscript of Binkowska *et al.* discussing the recent data on the safer venous thromboembolic (VTE) profile of oestradiol (E₂) containing hormone therapies compared to ethinylloestradiol (EE) or conjugated equine oestrogens (CEE) for their use in contraception or in the relief of menopausal symptoms [1]. While we fully agree with the authors about the epidemiological and biological data showing that oestradiol containing pills represent a safer alternative than EE regarding the risk of VTE, the physiopathological mechanism explaining these observations deserves further explanations [2]. The authors pointed out that this is in line with the observations of changes in individual biochemical markers elicited by these treatments [1]. Evaluation of individual markers of coagulation is not predictive of the VTE risk because of the multiple interactions in the coagulation cascade. In contrast, the VTE risk may correlate with the changes in global tests of coagulation which integrate all haemostatic changes [3].

The increased risk of VTE is mainly explained by the impact of oestrogens on the resistance towards activated protein C (APC) and on augmented thrombin generation [4–6]. Our group has recently demonstrated that a higher risk of VTE is observed with pills generating a higher APC resistance, as measured by the endogenous thrombin potential (ETP) based APC resistance test [5, 7, 8]. This has also been observed, although less objectively, by other teams [9]. The correlation between the APC resistance induced by estrogenic therapies and the risk of VTE is not surprising and has been demonstrated for many years [6].

Currently, there are 3 different oestrogens on the market used in combined oral contraceptives: EE, E₂ (and its valerate) and estetrol (E₄). In their manuscript,

Binkowska *et al.* aimed at discussing the most recent research findings in this area but failed to report E₄, this new oestrogenic molecule which has a particular pharmacodynamic and pharmacokinetic (PK) profile [1]. Estetrol is the first natural fetal oestrogen with a selective action in tissues (NEST) [10]. It acts as an agonist for the ER α nuclear receptor but is an antagonist of the membrane initiated steroid signalling (MISS) initiated by E₂ [11]. In contrast to the other oestrogens, it is not metabolized by CYP enzymes and does not give rise to carcinogenic nor to biologically active metabolites. These properties translate into clinical benefits such as absence of drug-drug interaction, lower risk of breast cancer and a small impact on the liver (including on lipid, glucose metabolism and haemostasis proteins) [11]. In contraception, E₄ 15 mg is associated with drospirenone (DRSP) 3 mg [12]. Its haemostatic impact, extensively studied during the clinical development programme [13–15], shows that E₄/DRSP has a lower impact on haemostasis than EE in association with either levonorgestrel (LNG) or DRSP [14, 15]. In silico modelling supports the hypothesis that E₄/DRSP has a relative risk (RR) of VTE compared to a non-user of around 1.6, which is lower than the RR of 2.2 to 2.4 observed with EE/LNG. This model also highlights the lower risk of VTE with E₂/norgestrel acetate, confirming its robustness to predict the risk of VTE (Fig. 1 A) [7].

Estetrol is also currently studied for its effective relief of menopausal symptoms [11]. Indeed, for menopausal therapy E₄ at the dose of 15 mg daily shows a limited impact on haemostasis parameters [16]. This is very interesting since again in this population, the risk of VTE associated with the use of oestrogen is related to APC resistance induced by hormonal therapies (HT) [17]. According to the data present-

Corresponding author:

Prof. **Jonathan Douxfils**, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium, e-mail: jonathan.douxfils@unamur.be

Submitted: 27.11.2022

Accepted: 28.11.2022




Fig. 1. A) Association between normalized activated protein C sensitivity ratio (nAPCsr) data and relative risk of venous thromboembolism in women using combined oral contraceptives; B) mean thrombogram [2.5th–97.5th percentile] of childbearing age women not using any hormonal contraception (baseline population) (n = 86; yellow) and mean thrombogram [95% CI of the mean] after 6 cycles of estetrol 15 mg associated with drospirenone 3 mg (n = 34; pink); C) mean thrombogram [2.5th–97.5th percentile] of untreated postmenopausal women (n = 168; orange) and mean thrombogram [95% CI of the mean] after 12 weeks of estetrol 15 mg (n = 32, red)

CI – confidence interval, COC – combined oral contraceptive, CPA – cyproterone acetate, DNG – dienogest, DRSP – drospirenone, DSG – desogestrel, EE – ethinylloestradiol, E_2 – oestradiol, E_4 – estetrol, GSD – gestodene, LNG – levonorgestrel, nAPCsr – normalized activated protein C sensitivity ratio, NOMAC – nomegestrol acetate, RR – relative risk, SD – standard deviation, VTE – venous thromboembolism

ed by Panay *et al.* there is a reduced risk of VTE with E_2 1 mg/P4 100 mg compared to CEE/medroxyprogesterone acetate [18]. Similar observations were made some years ago by Smith *et al.*, who reported an RR of VTE of 2.08 for CEE compared to E_2 [19]. This group also reported that the APC resistance was lower in E_2 users compared to CEE users. Thus, in terms of risk of VTE with HT, oral CEE can be categorized as the compound with the highest risk followed by oral E_2 and then transdermal E_2 [6, 19]. Similar to the observations in the field of contraception, the risk of VTE is also mainly explained by resistance towards APC. The fact that E_4 has a similar impact on ETP-based

APC resistance as transdermal E_2 is reassuring, since this new oestrogen may be classified as the first orally available HT with a low impact on haemostasis [16]. The recent data presented at the 20th World Congress of the International Society of Gynecological Endocrinology and at the 18th World Congress on Menopause of the International Menopause Society confirm this statement. These data show that E_4 , either associated with DRSP or alone, has a negligible and not clinically relevant impact on thrombin generation, a global coagulation test sensitive to the changes induced by oestrogenic compounds (Fig. 1 B, C) [15, 20]. Added to its low impact on APC resistance and the accumulating

evidence that these biological changes are associated with the increased risk of VTE observed in women on HT or combined hormonal contraceptives, E_4 represents an oestrogen with an expected low risk of VTE.

The oral intake of E_2 generates an unbalanced non-physiological oestrone/oestradiol ratio ($E_1/E_2 = 5$) in contrast to that observed in women with endogenous ovarian activity ($E_1/E_2 = 1$) [21, 22]. Importantly, during oral treatment, the first liver passage of oestrogens after rapid absorption in the gut is characterized by high local exogenous hepatic steroid levels, which are about 4-fold higher than the peripheral serum concentrations [23]. Moreover, owing to the high permeability of the hepatic microvasculature and the higher availability of protein-bound oestrogen for influx into the liver as compared to other organs [24, 25], the impact on hepatic metabolism of orally applied oestradiol is much higher than that of the transdermal route causing the well-known pro-thrombotic effect [17, 21]. This rapid conversion of E_2 into E_1 results in a high E_1/E_2 ratio and contributes to the prothrombotic impact of oral E_2 . Different groups indeed have shown a correlation between VTE risk and E_1 plasma levels [21, 26]. In addition, the carriers of the CYP3A5*1 allele which accelerates the E_2 into E_1 conversion have a 30-fold higher risk of VTE [26].

In summary, although E_2 use appears to be safer than EE or CEE, its oral administration leads to non-physiological, unbalanced metabolite formation, which contributes to the well-known adverse effects of E_2 on coagulation. The pharmacodynamic and PK characteristics of E_4 (absence of active metabolites such as E_3 , E_2 and E_1 , absence of hydroxy-metabolites and cancerogenic metabolites) indicate that E_4 may represent a safer oestrogen.

References

- Binkowska M, Jakimiuk A, Paszkowski T, et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. *Prz Menopauz* 2022; 21: 197-199.
- Grandi G, Facchinetti F, Bitzer J. Confirmation of the safety of combined oral contraceptives containing oestradiol on the risk of venous thromboembolism. *Eur J Contracept Reprod Health Care* 2022; 27: 83-84.
- Reda S, Morimont L, Douxfils J, et al. Can we measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests? *Hamostaseologie* 2020; 40: 364-378.
- Westhoff CL, Pike MC, Cremers S, et al. Endogenous thrombin potential changes during the first cycle of oral contraceptive use. *Contraception* 2017; 95: 456-463.
- Morimont L, Dogne JM, Douxfils J. Letter to the Editors-in-Chief in response to the article of Abou-Ismaïl, et al. entitled "Estrogen and thrombosis: a bench to bedside review" (*Thrombosis Research* 192 (2020) 40-51). *Thromb Res* 2020; 193: 221-223.
- Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. *Lancet* 1999; 354: 2036-2040.
- Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, et al. A novel estetrol-containing combined oral contraceptive: European expert panel review. *Eur J Contracept Reprod Health Care* 2022; 27: 373-383.
- Douxfils J, Morimont L, Delvigne AS, et al. Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. *Clin Chem Lab Med* 2020; 58: 294-305.
- Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. *Thromb Res* 2010; 126: 5-11.
- Douxfils J, Morimont L, Gaspard U, et al. Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation. *Thromb Res* 2022; S0049-3848(22)00387-5.
- Gerard C, Arnal JF, Jost M, et al. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. *Expert Rev Clin Pharmacol* 2022; 15: 121-137.
- European Medicines Agency. Drovelis – EPAR – Summary of Product Characteristics 2021.
- Kluft C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. *Contraception* 2017; 95: 140-147.
- Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. *Contraception* 2020; 102: 396-402.
- Morimont L, Jost M, Gaspard U, et al. Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. *J Clin Endocrinol Metab* 2022; 108(1):135-143.
- Douxfils J, Gaspard U, Taziaux M, et al. Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. *Climacteric* 2023; 26: 55-63.
- Canonic M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. *Maturitas* 2015; 82: 304-307.
- Panay N, Nappi RE, Palacios S, et al. Venous thromboembolism risk in menopausal women treated with oral estradiol/micronised progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the united states. 20th ISGE World Congress, 11.05.2022 – 14.05.2022, Florence 2022.
- Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. *JAMA Int Med* 2014; 174: 25-31.
- Morimont L. Low thrombin generation in menopausal women using estetrol (E4). 18th World Congress on Menopause 26–29.10.2022, Lisbon 2022.
- Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. *J Thromb Haemost* 2010; 8: 1736-1744.
- Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. *Climacteric* 2005; 8: 3-63.
- Back DJ, Breckenridge AM, Maclver M, et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. *Br J Clin Pharmacol* 1982; 13: 325-330.
- Steingold KA, Cefalu W, Pardridge W, et al. Enhanced hepatic extraction of estrogens used for replacement therapy. *J Clin Endocrinol Metab* 1986; 62: 761-766.
- Verheugen C, Pardridge WM, Judd HL, et al. Differential permeability of uterine and liver vascular beds to estrogens and estrogen conjugates. *J Clin Endocrinol Metab* 1984; 59: 1128-1132.
- Canonic M, Bouaziz E, Carcaillon L, et al. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. *J Clin Endocrinol Metab* 2008; 93: 3082-3087.